Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- India Scales Up HPV Vaccination, Screening in Cervical Cancer Elimination Push: Health Minister J.P. Nadda
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
Delhi High Court Declines FMC’s Plea to Halt Natco Pharma’s Insecticide Sales
The court noted that Natco had presented a credible challenge to the validity of the disputed patent claim and had already filed a revocation petition. As a result, FMC failed to establish a strong prima facie case necessary for interim relief.
- By Newsdesk
- New Delhi
- Nov 23, 2025
The Delhi High Court has refused to impose an interim ban on the sale of Natco Pharma’s insecticidal product following a patent infringement complaint by FMC Corporation. FMC argued that Natco’s formulation, Cyantraniliprole 10.26% OD, relied on a patented chemical intermediate protected under Claim 12 of Indian Patent IN-645, which is set to expire in December 2025.
The court noted that Natco had presented a credible challenge to the validity of the disputed patent claim and had already filed a revocation petition. As a result, FMC failed to establish a strong prima facie case necessary for interim relief. The judge also observed that Natco had invested significantly in manufacturing and regulatory approvals, and with the patent nearing expiry, the balance of convenience favoured allowing continued sales.
FMC maintained that Natco’s product infringed its process patent, but the court found that the questions surrounding the patent’s validity warranted a full trial rather than immediate restrictions. The ruling reflects the judiciary’s cautious approach to granting injunctions in patent disputes, especially where patent validity is under challenge and commercial stakes are high.